Transaction #24082 · Form 4 · 0001493152-25-028761
CDT Equity Inc. · Stock award · Pre-Funded Warrants
CDT Equity Inc. · Transacted December 8, 2025 · Filed December 22, 2025
What does this filing report?
An SEC Form 4 filing for CDT Equity Inc. records a stock award involving Pre-Funded Warrants on December 8, 2025. The reported quantity was 3,685,815. The filing date is December 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CDT Equity Inc.
- Company CIK
- 0001896212
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 3,685,815
- Reported price
- 0.0001
- Reference value
- 368.5815
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 3,685,815
- Ownership description
- By Corvus Capital Ltd.
- SEC acceptance time
- Dec 22, 2025, 4:05 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Corvus Capital Ltd. ↗
10% owner
CIK 0001990829
- Regan Andrew ↗
Chief Executive Officer · Director · 10% owner
CIK 0001991325
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 3,685,815
- Conversion / exercise price
- 0.0001
- Exercise date
- December 8, 2025
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.
- F2
- Based on the closing price per share of Common Stock on December 7, 2025.
- F3
- These shares of Common Stock are owned of record by Corvus.
- F4
- These shares of Common Stock are owned of record by Manoira Corporation ("Manoira").
- F5
- These shares of Common Stock are owned of record by Algo Holdings, Inc. ("Algo").
- F6
- Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein.
- F7
- Until exercised in full.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.